ReNewVax develops pneumococcal vaccines using a proprietary protein-based adjuvanted formulation to prevent life-threatening bacterial infections and combat antimicrobial resistance. Their lead program, RVX-001, aims to be the first universal vaccine for _Streptococcus pneumoniae_, with Phase 1 clinical trials expected to begin by the end of 2025.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
_Streptococcus pneumoniae_ causes life-threatening bacterial infections, and current vaccines do not offer universal protection, contributing to antimicrobial resistance. The development of broad-coverage pneumococcal vaccines is needed to combat the spread of resistant strains and reduce the global burden of pneumococcal disease.
Solution
ReNewVax is developing a novel protein-based adjuvanted vaccine, RVX-001, designed to provide broad protection against _Streptococcus pneumoniae_. This vaccine aims to overcome the limitations of existing pneumococcal vaccines by targeting multiple serotypes and reducing the reliance on antibiotics. By stimulating a robust immune response, RVX-001 has the potential to be a universal pneumococcal vaccine, preventing invasive bacterial infections and mitigating the rise of antimicrobial resistance. The company is also developing rationally-designed vaccines against _Streptococcus agalactiae_ (GBS) and _Streptococcus pyogenes_ (GAS).
Target Audience
The primary target audience includes individuals at risk of pneumococcal infections, such as infants, the elderly, and immunocompromised individuals, as well as public health organizations seeking to reduce the burden of pneumococcal disease.
Features
- RVX-001: A protein-based adjuvanted vaccine targeting _Streptococcus pneumoniae_
- Broad coverage against multiple pneumococcal serotypes
- Designed to induce a strong and durable immune response
- Aims to reduce the incidence of pneumococcal infections and antimicrobial resistance
- RVX-002: mRNA vaccine in preclinical studies targeting _Streptococcus agalactiae_ (GBS)
- RVX-003: Vaccine candidate selection in progress targeting _Streptococcus pyogenes_ (GAS)